Basis of Presentation - Additional Information (Details) - USD ($)	3 Months Ended			12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2021	Apr. 13, 2020	Dec. 31, 2019
Subsidiary, Sale of Stock [Line Items]
Derivative financial instruments, at estimated fair value—warrants				$ 0	$ 11,673
Change in fair value of derivative instrument-warrants				0	6,050
Total stockholders' equity	$ 102,643,766	$ 110,724,864	$ 117,580,017	92,995,003	40,520,391			$ 15,616,697
Cash				91,348,967	40,726,838
Accumulated deficit				133,501,295	104,105,463
Working Capital				89,200,000
Net cash used in operating activities				31,224,481	16,165,202
Net loss	9,269,473	7,667,105	6,063,517	32,722,168	20,353,938
Cumulative Effect, Period of Adoption, Adjustment
Subsidiary, Sale of Stock [Line Items]
Change in fair value of derivative instrument-warrants					(10,911)
Total stockholders' equity					11,673
Beneficial conversion feature					(7,844,643)
Cumulative Effect, Period of Adoption, Adjustment | July 3, 2018 Warrants
Subsidiary, Sale of Stock [Line Items]
Derivative financial instruments, at estimated fair value—warrants					(11,673)
Additional Paid in Capital
Subsidiary, Sale of Stock [Line Items]
Total stockholders' equity	224,714,238	223,524,863	222,712,911	224,787,547	142,910,523			97,651,006
Additional Paid in Capital | Cumulative Effect, Period of Adoption, Adjustment
Subsidiary, Sale of Stock [Line Items]
Total stockholders' equity					(3,314,663)
Additional Paid in Capital | Cumulative Effect, Period of Adoption, Adjustment | July 3, 2018 Warrants
Subsidiary, Sale of Stock [Line Items]
Total stockholders' equity					11,673
Additional Paid in Capital | Cumulative Effect, Period of Adoption, Adjustment | Warrants – liability classified
Subsidiary, Sale of Stock [Line Items]
Total stockholders' equity					4,529,980
Accumulated Deficit
Subsidiary, Sale of Stock [Line Items]
Total stockholders' equity	(123,779,223)	(114,509,750)	(106,842,645)	(133,501,295)	(104,105,463)			(83,751,525)
Net loss				32,722,168	20,353,938
Accumulated Deficit | Cumulative Effect, Period of Adoption, Adjustment
Subsidiary, Sale of Stock [Line Items]
Total stockholders' equity					3,326,336	$ 3,300,000
Accumulated Deficit | Cumulative Effect, Period of Adoption, Adjustment | Warrants – liability classified
Subsidiary, Sale of Stock [Line Items]
Total stockholders' equity					(4,529,980)
Series C | Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Total stockholders' equity	$ 845,320	$ 846,320	$ 846,320	$ 845,320	856,320			$ 861,033
Series C | Preferred Stock | Cumulative Effect, Period of Adoption, Adjustment
Subsidiary, Sale of Stock [Line Items]
Total stockholders' equity					$ 5,816
PPP loan
Subsidiary, Sale of Stock [Line Items]
Principal amount							$ 200,000
Interest rate (as percent)							0.98%